However, our report is the first to demonstrate the clinical significance of the molecular pathogenesis of CH-derived vs. non-CH tMN post-aHSCT, despite the predominant prevalence of TP53 mutations in the latter. This evidence concerns the gene TP53 and cyclic hematopoiesis.